Myelodysplastic syndrome (MDS) is an acquired bone marrow disorder characterized by
ineffective hematopoiesis and cellular dysfunction and has an increased risk of transforming …

Stem cell transplantation (SCT) may be the only curative option for patients with relapsed or
refractory leukaemia, that is, high-risk (HR) leukaemia. Several salvage regimens have been …

Cerca de 40% dos pacientes portadores de síndromes mielodisplásicas podem ser curados
com o transplante alogênico de medula óssea. Os resultados mais favoráveis podem ser …

We aimed to validate the MYelofibrosis SECondary to PV and ET prognostic model (MYSEC-
PM) in 159 patients with myelofibrosis secondary to polycythemia vera (PV) and essential …

Improvements in supportive care and the use of peripheral blood stem cells have increased
the safety of autologous transplantation, making it an effective therapy for more patients with …

During the last 15 years, important progress has been made in the understanding of the
biology and prognosis of myelodysplastic syndromes (MDS). It is a clonal disorder …

The EORTC Leukemia Group comprises more than 45 qualified haematology centres in
Europe. The group promotes cooperation with new centres from Central and Eastern Europe …

Background: Information and tools that help individualize assessments of risk are important
to counsel older patients with acute myeloid leukemia (AML) about their treatment options …

Die allogene Stammzelltransplantation (SZT) stellt momentan die einzige potentiell kurative
Therapieoption für Patienten mit einem Myelodysplastischen Syndrom und sekundärer AML …

Background. Allogeneic stem cell transplantation (alloSCT) is usually considered the only
curative treatment option for patients with advanced or transformed myelodysplasia (MDS) in …